Michael Kim
PharmD, MS HEOR
MANAGER, Value Evidence
Portland, OR
“Help others achieve their dreams and you will achieve yours."– Les Brown
Areas of Expertise
- Evidence Generation Strategy
- Real-World Evidence
- Value Communication & Scientific Dissemination
- Project Management
Biography
Michael serves as a Manager on the Value & Evidence team at AESARA.
Prior to AESARA, Michael completed a two-year Health Economics and Outcomes Research (HEOR) fellowship at Takeda Pharmaceuticals in partnership with the University of Illinois Chicago (UIC). During this time, he led the end-to-end design, execution, and dissemination of real-world studies across both rare and prevalent therapeutic areas. His experience spans the full product life cycle—from early pipeline planning and launch readiness to post-market RWE and loss of exclusivity strategy.
With a strong foundation in pharmacy and HEOR, Michael brings expertise in evidence generation, product strategy, and cross-functional project leadership—driving high-impact value and access solutions that influence payer decision-making.
Key accomplishments
- ISPOR Montreal Student Research Competition Champions (2025)
- ISPOR – UIC Student Chapter Award for Excellence in Research: Scientific Poster Session Award Winner (2024)
- ISPOR – UIC Student Chapter Vice President (2024)
- AMCP Nexus – Poster Presentation Finalist (2024)
- UIC – Rho Chi Honor Society (2024)
- National AMCP P&T Competition Top 5 Finalist (2023)
- AMCP – USC Student Chapter President (2023)
Key publications
- Liu, Y., Kim, M., De Los Santos, B., Manne, S., Gandhi, V., Lu, M., & Martin, M. (2025, September 17–21). Antidepressant treatment patterns among patients with depression: A retrospective analysis of US health insurance claims and electronic health records data [Poster presentation]. Psych Congress 2025, San Diego, CA.
- Liu, Y., De Los Santos, B., Kim, M., Manne, S., Gandhi, V., Lu, M., & Martin, M. (2025, September 17–21). Prevalence of residual symptoms in adults with depression or major depressive disorder on antidepressant monotherapy: A retrospective, longitudinal analysis of US health insurance claims and electronic health records data [Poster presentation]. Psych Congress 2025, San Diego, CA.
- Gold, B. D., Jensen, E. T., Goodwin, B., Liu, E., Kim, M., Schwartz, T., Schaeffer‑Koziol, C., Terreri, B., & Baptist, A. (2025, May 13–16). Eosinophilic esophagitis‑related healthcare resource utilization: A retrospective cohort study of US health insurance claims data [Poster presentation]. ISPOR Annual Meeting, Montreal, QC, Canada.
- Shah, K., Kim, S., Richardson, M., Lee, W., Kim, M., De Los Santos, B., Wasfy, J., Nikitin, D., Rind, D., Touchette, D., & Winn, A. (2025, May 13–16). Cost‑effectiveness of transthyretin stabilizing agents for the treatment of ATTR‑CM [Podium presentation]. ISPOR Annual Meeting, Montreal, QC, Canada.
- Gold, B. D., Jensen, E. T., Goodwin, B., Liu, Y., Kim, M., Schwartz, T., Schaeffer‑Koziol, C., Terreri, B., & Baptist, A. (2025, May 3–6). Demographics and social determinants of health for patients with eosinophilic esophagitis: A retrospective cohort study of US health insurance claims data [Poster presentation]. Digestive Disease Week (DDW) 2025, Chicago, IL.
- Kim, M., De Los Santos, B., Alsharif, A., Perez, A., & Touchette, D. (2024, November 17–20). Assessing the quality of health economic studies in clinical pharmacy services: A qualitative analysis [Poster presentation]. ISPOR Europe Conference, Barcelona, Spain.
- Kim, M., & Kim, K. (2024, October 15–16). Trends in chronic kidney disease stage‑specific costs between nondiabetic and diabetic individuals [Poster presentation]. Academy of Managed Care Pharmacy (AMCP) Nexus Conference, Las Vegas, NV.
- Kim, M., & Kim, K. (in preparation). Real‑World Healthcare costs and resource utilization following initiation of icosapent ethyl vs. omega‑3 acid ethyl esters in the United States.
- Sarker, J., Kim, M., Patton, S., Radwański, B., Munger, M., & Kim, K. Comparative risk of the onset of atrial fibrillation after icosapent ethyl versus omega‑3 acid ethyl esters adjuvant to statins. Journal of the American Heart Association.
- De Los Santos, B., Kim, M., Alsharif, A., Touchette, D., & Perez, A. A systematic review of economic evaluations of clinical pharmacy services in the United States: 2018–2022. Journal of the American College of Clinical Pharmacy.
- Win, T. T., Nakanishi, R., Osawa, K., Li, D., Susaria, S. S., Jayawardena, E., Hamal, S., Kim, M., Broersen, A., Kitslaar, P. H., Dailing, C., & Budoff, M. J. (2019). Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial). American Heart Journal, 212, 129–133. https://doi.org/10.1016/j.ahj.2019.02.014
- Nakanishi, R., Post, W. S., Osawa, K., Jayawardena, E., Kim, M., Sheidaee, N., Nezarat, N., Rahmani, S., Kim, N., Hathiramani, N., Susarla, S., Palella, F., Witt, M., Blaha, M. J., Brown, T. T., Kingsley, L., Haberlen, S. A., Dailing, C., & Budoff, M. J. (2018). Multicenter AIDS Cohort Study Quantitative Coronary Plaque Progression Study: Rationale and design. Coronary Artery Disease, 29(1), 23–29. https://doi.org/10.1097/MCA.0000000000000546
- Nezarat, N., Kim, M., & Budoff, M. (2017). Role of coronary calcium for risk stratification and prognostication. Current Treatment Options in Cardiovascular Medicine, 19(2), 8. https://doi.org/10.1007/s11936-017-0509-7
Education
- MS, Pharmacy (HEOR), University of Illinois Chicago
- Post-doctoral HEOR fellowship, Takeda Pharmaceuticals
- PharmD, Pharmacy, University of Southern California
- BA, Psychology, University of California Irvine
My letter
Delta (Δ) represents change, transformation, and forward momentum—a perfect reflection of my commitment to driving meaningful impact through evidence, innovation, and continuous growth. In both research and relationships, I strive to be a catalyst for positive change, embracing adaptability and progress in everything I do.
